MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine.
Neurol Sci
; 42(9): 3533-3535, 2021 Sep.
Article
in English
| MEDLINE | ID: covidwho-1281288
ABSTRACT
BACKGROUND:
The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs' immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as the post-infection development of immunity against the virus under these treatments due to their interaction with the immune system.METHODS:
We report two asymptomatic cases of COVID-19 in patients with relapsing-remitting multiple sclerosis (RRMS) shortly after starting cladribine therapy, both developed anti-SARS-CoV-2 antibody response.RESULTS:
Patients with MS who are under newly initiated treatment with cladribine tablets may experience an asymptomatic COVID-19 infection and they may develop immunity against SARS-CoV-2.CONCLUSION:
These observations raise the probability that DMTs with immunosuppressive effects, such as cladribine, may be considered as a treatment option for selected MS patients with high disease activity during the COVID-19 pandemic.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Multiple Sclerosis, Relapsing-Remitting
/
COVID-19
/
Multiple Sclerosis
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Neurol Sci
Journal subject:
Neurology
Year:
2021
Document Type:
Article
Affiliation country:
S10072-021-05409-6
Similar
MEDLINE
...
LILACS
LIS